Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Rhea-AI Summary
Health Catalyst (Nasdaq: HCAT) signed a definitive agreement to divest its mid-revenue cycle business, Vitalware, to Med-Metrix for $147 million in cash. The company expects this move to sharpen its focus on core technology and AI-driven healthcare improvement.
Net proceeds plus cash on hand are planned to fully repay and terminate a ~$160 million senior secured term loan, which Health Catalyst expects will strengthen its balance sheet and increase financial flexibility. Vitalware generated approximately $37 million in fiscal 2025 revenue. Closing is expected in 2026, subject to specified conditions and regulatory waiting periods.
AI-generated analysis. Not financial advice.
Positive
- Divestiture of Vitalware for $147 million in cash
- Plan to fully repay ~$160 million senior secured term loan
- Expected stronger balance sheet and higher financial flexibility
- Strategy refocused on core technology and AI investments
- Leverages 18 years of proprietary healthcare improvement data and $2.8 billion in measured outcomes
Negative
- Sale of Vitalware removes a business with ~$37 million FY 2025 revenue
- Transaction closing expected in 2026 and remains subject to regulatory waiting periods and other conditions
News Market Reaction – HCAT
On the day this news was published, HCAT gained 45.86%, reflecting a significant positive market reaction. Argus tracked a peak move of +18.0% during that session. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $52M to the company's valuation, bringing the market cap to $164.78M at that time. Trading volume was exceptionally heavy at 49.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HCAT was down 1.48% pre-announcement. Several health information peers (SOPH, LFMD, CCLD, MNDR, SLP) also showed declines, but no names appeared in the momentum scanner, and scanner data flags this as not a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 2026 earnings | Neutral | +7.3% | Mixed Q1 results with revenue decline but stronger Adjusted EBITDA and guidance. |
| May 01 | Earnings call notice | Neutral | +16.0% | Announcement of Q1 2026 results release date and conference call details. |
| Apr 30 | Board appointment | Positive | -1.6% | Appointment of Steve Nelson of Aetna to the Board of Directors. |
| Mar 12 | FY 2025 results | Negative | -26.3% | 2025 results with modest revenue growth but wider net loss and lower retention. |
| Mar 02 | Earnings call notice | Neutral | +3.7% | Notice of Q4 and year-end 2025 earnings release and conference call. |
Recent news reactions mostly aligned with the tone of announcements, with one negative reaction to a governance/board update.
Over the past few months, Health Catalyst reported Q4 2025 results with $311.1M revenue and higher Adjusted EBITDA but a wider GAAP net loss, which was followed by a significant share price drop. Q1 2026 results showed $70.8M revenue and improved Adjusted EBITDA, prompting a positive reaction. The company also navigated leadership and board changes and guided 2026 revenue to $260–$265M. Today’s divestiture of Vitalware and planned debt repayment fits into this broader strategic and operational transformation narrative.
Market Pulse Summary
The stock surged +45.9% in the session following this news. A strong positive reaction aligns with a balance-sheet-focused divestiture that brings in $147 million of cash and is earmarked to help fully repay an approximately $160 million senior secured term loan. This follows a period of strategic review and mixed financial results, including wider GAAP losses but improving Adjusted EBITDA. Investors should watch execution on AI and core technology focus, integration of the new capital structure, and future earnings updates for confirmation.
Key Terms
senior secured term loan facility financial
form 8-k regulatory
regulatory waiting periods regulatory
AI-generated analysis. Not financial advice.
Transaction reflects a sharper focus on AI and core technology; net proceeds expected to strengthen balance sheet and provide financial flexibility
SALT LAKE CITY, June 04, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT) today announced it has signed a definitive agreement to divest Vitalware, LLC and the Vitalware business unit, its mid-revenue cycle business, to Med-Metrix for a total consideration of
“This is a big step forward for Health Catalyst. We are concentrating our business around the areas where we have the deepest conviction, and we plan to put the capital structure in place to back our long-term strategy. Vitalware is a great business, and we are pleased to have found a partner in Med-Metrix who is well positioned to carry it forward.”
— Ben Albert, CEO, Health Catalyst
Health Catalyst expects the transaction to strengthen its balance sheet and provide increased financial flexibility to prioritize the core technology and AI investments. At its core, the Company’s strategy is built on 18 years of proprietary healthcare improvement data and
The Company plans to use net proceeds from the divestiture upon closing, combined with cash on hand, to fully repay and terminate its existing senior secured term loan facility of approximately
Med-Metrix, a technology-enabled revenue cycle management company serving provider organizations across the country, will acquire Vitalware. Med-Metrix's resources and focus in revenue cycle management position it to invest in the business more deeply. A best-in-KLAS leader with approximately
The transaction is expected to close in 2026 subject to the satisfaction of certain specified closing conditions, including the expiration or termination of regulatory waiting periods. Additional details regarding the divestiture are included in Health Catalyst’s Form 8-K filed with the Securities and Exchange Commission (“SEC”) on June 4, 2026.
About Vitalware
Vitalware by Health Catalyst is a suite of mid-revenue solutions that help hospitals and health systems improve coding compliance, chargemaster management, charge capture, and price transparency across the mid-revenue cycle. It combines healthcare-specific data models, applied AI, and expert support to deliver measurable financial and operational results.
About Health Catalyst
Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company that accelerates measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and
Advisors
Raymond James served as the exclusive financial advisor, and Latham & Watkins LLP served as outside legal counsel for Health Catalyst.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding Health Catalyst’s ability to close on the terms contemplated and the timing of the closing of the divestiture of Vitalware, the expected benefits from the divestiture of Vitalware (including increased financial flexibility), the planned use of proceeds from the divestiture, including the planned repayment and termination of its existing senior secured term loan facility, and Health Catalyst’s ability to execute on its strategic transformation, strategic priorities, long-term strategy, and growth. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Important risks and uncertainties that could cause actual results to differ materially from Health Catalyst’s expectations, plans and prospects, including the benefits that will be derived from this transaction, include without limitation, conditions to closing the divestiture not being satisfied, the failure to obtain regulatory approval with respect to the transaction, Health Catalyst not receiving the expected benefits from the divestiture, and the risk of adverse and unpredictable macro-economic conditions. For a detailed discussion of the risk factors that could affect Health Catalyst’s actual results, please refer to the risk factors identified in Health Catalyst’s SEC reports, including, but not limited to, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 11, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026 and further amended on April 30, 2026. All information provided in this release is as of the date hereof, and Health Catalyst undertakes no duty to update or revise this information unless required by law.
Health Catalyst Investor Relations Contact:
Stephanie St. Clair
Finance and Investor Relations, SVP
+1 (855)-309-6800
ir@healthcatalyst.com
Health Catalyst Media Contact
Kay Blazar
VP, PR
SVM PR & Marketing
Healthcatalyst@SVMPR.com
